A citation-based method for searching scientific literature

Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees, Patricia Limousin, Thomas Foltynie. J Clin Invest 2013
Times Cited: 281







List of co-cited articles
1479 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Mark L Wahlqvist, Meei-Shyuan Lee, Chih-Cheng Hsu, Shao-Yuan Chuang, Jiunn-Tay Lee, Hsin-Ni Tsai. Parkinsonism Relat Disord 2012
149
13

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Chenhui Ji, Guo-Fang Xue, Cao Lijun, Peng Feng, Dongfang Li, Lin Li, Guanglai Li, Christian Hölscher. Brain Res 2016
62
20

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.
Simon C Cork, James E Richards, Marie K Holt, Fiona M Gribble, Frank Reimann, Stefan Trapp. Mol Metab 2015
224
12

Entry of exendin-4 into brain is rapid but may be limited at high doses.
A J Kastin, V Akerstrom. Int J Obes Relat Metab Disord 2003
255
12

A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jaishree Jalewa, Mohit Kumar Sharma, Simon Gengler, Christian Hölscher. Neuropharmacology 2017
46
26

Insulin resistance impairs nigrostriatal dopamine function.
J K Morris, G L Bomhoff, B K Gorres, V A Davis, J Kim, P-P Lee, W M Brooks, G A Gerhardt, P C Geiger, J A Stanford. Exp Neurol 2011
93
12

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
12



Diabetes and the risk of developing Parkinson's disease in Denmark.
Eva Schernhammer, Johnni Hansen, Kathrine Rugbjerg, Lene Wermuth, Beate Ritz. Diabetes Care 2011
119
12

Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.
E Cereda, M Barichella, E Cassani, R Caccialanza, G Pezzoli. Neurology 2012
91
13

A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
Lijun Cao, Dongfang Li, Peng Feng, Lin Li, Guo-Fang Xue, Guanglai Li, Christian Hölscher. Neuroreport 2016
50
24


Parkinson disease.
Werner Poewe, Klaus Seppi, Caroline M Tanner, Glenda M Halliday, Patrik Brundin, Jens Volkmann, Anette-Eleonore Schrag, Anthony E Lang. Nat Rev Dis Primers 2017
12

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Shuchun Chen, Seong-Jin Yu, Yazhou Li, Daniela Lecca, Elliot Glotfelty, Hee Kyung Kim, Ho-Il Choi, Barry J Hoffer, Nigel H Greig, Dong Seok Kim,[...]. Sci Rep 2018
29
37

Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.
I Moroo, T Yamada, H Makino, I Tooyama, P L McGeer, E G McGeer, K Hirayama. Acta Neuropathol 1994
116
11


Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.
Kathleen T Watson, Tonita E Wroolie, Gabby Tong, Lara C Foland-Ross, Sophia Frangou, Manpreet Singh, Roger S McIntyre, Siena Roat-Shumway, Alison Myoraku, Allan L Reiss,[...]. Behav Brain Res 2019
43
25


GLP-1 receptor agonists for Parkinson's disease.
Caroline A Mulvaney, Gonçalo S Duarte, Joel Handley, David Jw Evans, Suresh Menon, Richard Wyse, Hedley Ca Emsley. Cochrane Database Syst Rev 2020
18
61

Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study.
Ruth Brauer, Krishnan Bhaskaran, Nishi Chaturvedi, David T Dexter, Liam Smeeth, Ian Douglas. PLoS Med 2015
82
12

GLP-1 secretion by microglial cells and decreased CNS expression in obesity.
Camilla Kappe, Linda M Tracy, Cesare Patrone, Kerstin Iverfeldt, Åke Sjöholm. J Neuroinflammation 2012
62
16

Saxagliptin: a novel antiparkinsonian approach.
Noha N Nassar, Muhammad Y Al-Shorbagy, Hany H Arab, Dalaal M Abdallah. Neuropharmacology 2015
59
16



Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling.
Aileen M Moloney, Rebecca J Griffin, Suzanne Timmons, Rosemary O'Connor, Rivka Ravid, Cora O'Neill. Neurobiol Aging 2010
518
10

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?
Eric Steen, Benjamin M Terry, Enrique J Rivera, Jennifer L Cannon, Thomas R Neely, Rose Tavares, X Julia Xu, Jack R Wands, Suzanne M de la Monte. J Alzheimers Dis 2005
10

Glitazone use associated with reduced risk of Parkinson's disease.
Brage Brakedal, Irene Flønes, Simone F Reiter, Øivind Torkildsen, Christian Dölle, Jörg Assmus, Kristoffer Haugarvoll, Charalampos Tzoulis. Mov Disord 2017
64
15

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.
Jessica Freiherr, Manfred Hallschmid, William H Frey, Yvonne F Brünner, Colin D Chapman, Christian Hölscher, Suzanne Craft, Fernanda G De Felice, Christian Benedict. CNS Drugs 2013
309
10

The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
Caitriona M Long-Smith, Sean Manning, Paula L McClean, Meghan F Coakley, Domhnall J O'Halloran, Christian Holscher, Cora O'Neill. Neuromolecular Med 2013
107
10


Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.
Ghada A Badawi, Mai A Abd El Fattah, Hala F Zaki, Moushira I El Sayed. Inflammopharmacology 2017
54
18


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
10


Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.
Therese S Salameh, Elizabeth M Rhea, Konrad Talbot, William A Banks. Biochem Pharmacol 2020
21
47

Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors.
Lindsay Joy Spielman, Deanna Lynn Gibson, Andis Klegeris. Eur J Cell Biol 2017
49
18

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.
Abba J Kastin, Victoria Akerstrom, Weihong Pan. J Mol Neurosci 2002
344
9

Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis.
Yazhou Li, Srinivasulu Chigurupati, Harold W Holloway, Mohamed Mughal, David Tweedie, Daniel A Bruestle, Mark P Mattson, Yun Wang, Brandon K Harvey, Balmiki Ray,[...]. PLoS One 2012
83
10


Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.
Hong-Yan Cai, Jun-Ting Yang, Zhao-Jun Wang, Jun Zhang, Wei Yang, Mei-Na Wu, Jin-Shun Qi. Biochem Biophys Res Commun 2018
47
19

DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.
Yue Cao, Christian Hölscher, Meng-Ming Hu, Ting Wang, Fang Zhao, Yu Bai, Jun Zhang, Mei-Na Wu, Jin-Shun Qi. Eur J Pharmacol 2018
36
25

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.
Henrik H Hansen, Katrine Fabricius, Pernille Barkholt, Michael L Niehoff, John E Morley, Jacob Jelsing, Charles Pyke, Lotte Bjerre Knudsen, Susan A Farr, Niels Vrang. J Alzheimers Dis 2015
103
9

Shared dysregulated pathways lead to Parkinson's disease and diabetes.
Jose A Santiago, Judith A Potashkin. Trends Mol Med 2013
138
9

Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Henrik H Hansen, Katrine Fabricius, Pernille Barkholt, Jens D Mikkelsen, Jacob Jelsing, Charles Pyke, Lotte Bjerre Knudsen, Niels Vrang. Brain Res 2016
28
32


Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
531
9

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
Suzanne Craft, Laura D Baker, Thomas J Montine, Satoshi Minoshima, G Stennis Watson, Amy Claxton, Matthew Arbuckle, Maureen Callaghan, Elaine Tsai, Stephen R Plymate,[...]. Arch Neurol 2012
827
9

Obesity, diabetes, and risk of Parkinson's disease.
Natalia Palacios, Xiang Gao, Marjorie L McCullough, Eric J Jacobs, Alpa V Patel, Tinisha Mayo, Michael A Schwarzschild, Alberto Ascherio. Mov Disord 2011
100
9

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen,[...]. N Engl J Med 2019
563
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.